Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer’s Disease Continuum Using Patient-Caregiver Dyad Surveys
Open Access
- 16 April 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 99 (1) , 191-206
Abstract
Background: Alzheimer’s disease (AD) and mild cognitive impairment (MCI) have negative quality of life (QoL) and economic impacts on patients and their caregivers and may increase along the disease continuum from MCI to mild, moderate, and severe AD. Objective: To assess how patient and caregiver QoL, indirect and intangible costs are associated with MCI and AD severity. Methods: An on-line survey of physician-identified patient-caregiver dyads living in the United States was conducted from June–October 2022 and included questions to both patients and their caregivers. Dementia Quality of Life Proxy, the Care-related Quality of Life, Work Productivity and Activity Impairment, and Dependence scale were incorporated into the survey. Regression analyses investigated the association between disease severity and QoL and cost outcomes with adjustment for baseline characteristics. Results: One-hundred patient-caregiver dyads were assessed with the survey (MCI, n = 27; mild AD, n = 27; moderate AD, n = 25; severe AD, n = 21). Decreased QoL was found with worsening severity in patients ( p < 0.01) and in unpaid (informal) caregivers ( n = 79; p = 0.02). Dependence increased with disease severity ( p < 0.01). Advanced disease severity was associated with higher costs to employers ( p = 0.04), but not with indirect costs to caregivers. Patient and unpaid caregiver intangible costs increased with disease severity ( p < 0.01). A significant trend of higher summed costs (indirect costs to caregivers, costs to employers, intangible costs to patients and caregivers) in more severe AD was observed ( p < 0.01). Conclusions: Patient QoL and functional independence and unpaid caregiver QoL decrease as AD severity increases. Intangible costs to patients and summed costs increase with disease severity and are highest in severe AD.Keywords
This publication has 53 references indexed in Scilit:
- 2023 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2023
- Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare SystemNeurology and Therapy, 2022
- The Humanistic and Economic Burden of Alzheimer's DiseaseNeurology and Therapy, 2022
- Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)Alzheimer's & Dementia, 2021
- US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samplesQuality of Life Research, 2020
- Diagnostic accuracy of the Clinical Dementia Rating Scale for detecting mild cognitive impairment and dementia: A bivariate meta‐analysisInternational Journal of Geriatric Psychiatry, 2020
- Marital status and cognitive impairment in the United States: evidence from the National Health and Aging Trends StudyAnnals of Epidemiology, 2019
- Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and USPharmacoEconomics, 2016
- The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carersQuality of Life Research, 2014
- The relationship between changes in quality of life outcomes and progression of Alzheimer's disease: results from the Dependence in AD in England 2 longitudinal studyInternational Journal of Geriatric Psychiatry, 2014